Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, which speaks to the promise of the FDA-approved garadacimab.
Timothy Craig, DO
Advertisement
Professor, Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, and Professor, Department of Pediatrics at Penn State University
Articles by Timothy Craig, DO
The recent approval of garadacimab can help to treat patients with hereditary angioedema (HAE) along with sebetralstat, which is awaiting FDA approval, explains Timothy Craig, DO, Penn State Health.
With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers
3
Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma
4
Health Equity & Access Weekly Roundup: June 26, 2026
5